Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I clinical trial is studies the side effects and best dose of giving veliparib
together with temozolomide in treating patients with acute leukemia. Veliparib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as temozolomide, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving veliparib
together with temozolomide may kill more cancer cells.